bluuebunny/crossref_metadata_2025_split huggingface dataset:
Unveiling Neurobrucellosis: A Case Report Emphasizing Early Diagnosis for Better Outcomes
Authors: SIVAKUMAR HARIPRIYA , MALHOTRA SHIKHIR , GADEPALLI RAVISEKHAR , TAK VIBHOR , KUMAR BHARAT 
Published: September 2023

Introduction:Brucellosis is a pervasive zoonotic disease causing considerable human morbidity worldwide. This report focuses on a case of Neurobrucellosis in a rural Indian patient, emphasizing the need for timely microbiological confirmation given its nonspecific clinical presentation.
Case Presentation: A 55-year-old rural Indian farmer presented with a three-week history of insidious, low-grade fever, myalgia, and arthralgia. He developed acute right-sided weakness and neurological symptoms, including disorientation and neck rigidity. Laboratory tests indicated abnormal blood counts, elevated inflammatory markers, and liver dysfunction. Cerebrospinal fluid analysis showed pleocytosis with lymphomononuclear cells and elevated protein levels. Blood cultures eventually grew Gram-negative coccobacilli. Serological tests confirmed neurobrucellosis. Prompt antibiotic therapy led to clinical and laboratory improvement.
Conclusion: This case underscores the importance of recognizing neurobrucellosis, particularly in endemic areas, given its nonspecific clinical presentation. Early microbiological diagnosis, supported by positive blood cultures and serological tests, was crucial. The patient's rapid response to appropriate antibiotics emphasizes the significance of timely recognition and management.
Sphingomonas oryzagri sp. nov., isolated from a rice field
Authors: Huq Md. Amdadul , Lee Sun-Young , Rahman Md. Shahedur , Akter Shahina 
Published: September 2023

A Gram-stain-negative, aerobic, short rod-shaped and motile novel bacterial strain, designated MAHUQ-71T, was isolated from the soil of a rice field. The colonies were observed to be milky yellow-coloured, smooth, spherical and 0.1–0.4 mm in diameter when grown on Reasoner's 2A agar medium for 2 days. Strain MAHUQ-71T was found to be able to grow at 15–37 °C, pH 5.0–10.0 and with 0–3.0 % NaCl (w/v). The strain was found to be positive for the catalase test, but negative for the oxidase test. The strain was positive for hydrolysis of aesculin and Tween 20. According to the 16S rRNA gene sequence comparisons, the isolate was identified as a member of the genus

Sphingomonas

and to be closely related to

Sphingomonas chungangi

MAH-6T (98.5 % sequence similarity),

Sphingomonas polyaromaticivorans

B2-7T (98.4 %) and

Sphingomonas oligoaromativorans

SY-6T (96.6 %). Strain MAHUQ-71T has a draft genome size of 4 255 278 bp (10 contigs), annotated with 4098 protein-coding genes, 47 tRNA and three rRNA genes. The average nucleotide identity (ANI) and digital DNA–DNA hybridization (dDDH) values between strain MAHUQ-71T and the closest type strain

S. chungangi

MAH-6T were in the range of 85.6 and 30.6 %, respectively. The genomic DNA G+C content was determined to be 66.7 mol%. The predominant isoprenoid quinone was ubiquinone 10. The major fatty acids were identified as summed feature 8 (C18 : 1
ω7c and/or C18 : 1
ω6c), C16 : 0 and C14 : 0 2OH. The main polar lipids were phosphatidylcholine, phosphatidylethanolamine, diphosphatidylglycerol and sphingoglycolipid. On the basis of dDDH and ANI values, as well as the results of genotypic, chemotaxonomic and physiological analyses, strain MAHUQ-71T represents a novel species within the genus

Sphingomonas

, for which the name Sphingomonas oryzagri sp. nov. is proposed, with MAHUQ-71T (=KACC 22252T=CGMCC 1.19065T) as the type strain.
Tetraspanin CD81 promotes leukemia stem cell function and represents a new therapeutic vulnerability in acute myeloid leukemia
Authors: Gonzales Fanny , Peyrouze Pauline , Boyer Thomas , Guihard Soizic , Sevrin Francois , Laurent Djohana , Plesa Adriana , Barthelemy Adeline , Bongiovanni Antonino , Pottier Nicolas , Preudhomme Claude , Duployez Nicolas , Berthon Céline , Roumier Christophe , Cheok Meyling 
Published: September 2023

AbstractDespite important progress over the last decade, acute myeloid leukemia (AML) is still associated with poor clinical outcome. Novel potent therapies ideally effective against AML stem cells (LSC), a major driver of leukemia initiation and progression, are urgently needed. In particular, targeting common AML-associated antigens at the stem and progenitor cell level represents an attractive therapeutic strategy to achieve deep long-term remissions and is currently the subject of intensive research efforts. In this study, we identified the tetraspanin CD81, a cell surface antigen frequently expressed on AML cells including LSC, as a new determinant of relapse and poor prognosis. CD81 expression was higher in AML cells compared to normal bone marrow cells, and more markedly expressed at relapse. We further showed that modulation of CD81 expression using gain- and loss-of-function approaches affected leukemia aggressiveness, tumor burden, LSC-homing and - xenoengraftment as well as mouse survival. Finally, anti-hCD81 monoclonal antibody-treatment combined with standard chemotherapy in mice with pre-established AML not only reduced leukemia burden but also prolonged relapse-free and overall survival. Collectively, these results identified a new efficacious and safe pharmacological strategy for targeting LSC, opening up novel therapeutic avenues to improve AML outcome.Key pointsCD81 expression in AML including LSC is a new determinant of aggressive disease and poor prognosis.Anti-hCD81 monoclonal antibody-treatment of AML xenografts reduced leukemia burden and improved survival rates.
The Healthy Brain Initiative (HBI): A prospective cohort study protocol
Authors: Besser Lilah M. , Chrisphonte Stephanie , Kleiman Michael J. , O’Shea Deirdre , Rosenfeld Amie , Tolea Magdalena , Galvin James E. 
Published: September 2023

AbstractBackgroundThe Health Brain Initiative (HBI), established by University of Miami’s Comprehensive Center for Brain Health (CCBH), follows racially/ethnically diverse older adults without dementia living in South Florida. With dementia prevention and brain health promotion as an overarching goal, HBI will advance scientific knowledge by developing novel assessments and non-invasive biomarkers of Alzheimer’s disease and related dementias (ADRD), examining additive effects of sociodemographic, lifestyle, neurological and biobehavioral measures, and employing innovative, methodologically advanced modeling methods to characterize ADRD risk and resilience factors and transition of brain aging.MethodsHBI is a longitudinal, observational cohort study that will follow 500 deeply-phenotyped participants annually to collect, analyze, and store clinical, cognitive, behavioral, functional, genetic, and neuroimaging data and biospecimens. Participants are ≥50 years old; have no, subjective, or mild cognitive impairment; have a study partner; and are eligible to undergo magnetic resonance imaging (MRI). Recruitment is community-based including advertisements, word-of-mouth, community events, and physician referrals. At baseline, following informed consent, participants complete detailed web-based surveys (e.g., demographics, health history, risk and resilience factors), followed by two half-day visits which include neurological exams, cognitive and functional assessments, an overnight sleep study, and biospecimen collection. Structural and functional MRI is completed by all participants and a subset also consent to amyloid PET imaging. Annual follow-up visits repeat the same data and biospecimen collection as baseline, except that MRIs are conducted every other year after baseline.Ethics and expected impactHBI has been approved by the University of Miami Miller School of Medicine Institutional Review Board. Participants provide informed consent at baseline and are re-consented as needed with protocol changes. Data collected by HBI will lead to breakthroughs in developing new diagnostics and therapeutics, create comprehensive diagnostic evaluations, and provide the evidence base for precision medicine approaches to dementia prevention with individualized treatment plans.
Outcomes Following Surgical Repair of Sinus Venosus Atrial Septal Defects: A Systematic Review
Authors: El-Andari Ryaan , Moolla Muhammad , John Kevin , Slingerland Ashley , Campbell Sandra , Nagendran Jeevan , Mathew Anoop 
Published: September 2023

AbstractBackgroundSinus venosus atrial septal defect (SVASD) is a rare congenital cardiac anomaly comprising 5- 10% of all atrial septal defects. Although surgical closure is the standard treatment, data on outcomes have been confined to small cohorts.MethodsWe conducted a systematic review and meta-analysis of studies reporting the outcomes of surgical repair of SVASD. The primary outcome was mortality. Secondary outcomes encompassed atrial fibrillation, sinus node dysfunction, pacemaker insertion, cerebrovascular accident (CVA), reoperation, residual septal defect, superior vena cava (SVC) obstruction, and reimplanted pulmonary vein obstruction, occurring after surgical repair of SVASD. Pooled incidences of outcomes were calculated using a random effects model.ResultsForty studies involving 1,292 patients who underwent SVASD repair were included. The majority were male (59.4%), with 92.9% presenting with associated pulmonary anomalous venous connection. The weighted mean ages were 18.6 ± 12.5 years, and the overall weighted mean follow-up period was 8.6 ± 10.4 years. In-hospital mortality rate was 0.24%, with a 30-day mortality of 0.56% reported in 720 patients. Incidences of atrial fibrillation, sinus node dysfunction, pacemaker insertion, and CVA over the long-term follow-up were 2% (1-3%), 4% (2-6%), 2% (1-2%), respectively. Reoperation, residual septal defect, SVC obstruction, and reimplanted pulmonary vein obstruction occurred in 1% (0-2%), 2% (2-2%), 1% (1-1%), and 2% (2-2%) surgeries, respectively.ConclusionsThis is the first comprehensive analysis of outcomes following surgical repair of SVASD. The findings affirm the safety and effectiveness of surgery, establishing a reference point for evaluating emerging transcatheter therapies. Comparable safety and efficacy profiles to surgical repair are essential for widespread adoption of transcatheter treatments.
Effectiveness of Hyperbaric Oxygen Therapy Compared to Surgical Free Tissue Flap for Osteoradionecrosis of the Jaw: A Meta-Analysis
Authors: Sheth Megha K. , Collet Casey , Lin De-Chen , Sinha Uttam K. 
Published: September 2023

ABSTRACTBackgroundOsteoradionecrosis (ORN) of the jaw is an uncommon but potentially serious complication of radiation therapy for head and neck cancer, with many cases presenting months to years after completion of radiotherapy. ORN-related morbidity is high, making effective management of osteoradionecrosis essential. Current treatment options include hyperbaric oxygen therapy (HBOT), surgical management (free flap), and PENTOCLO, among others. Our goal is to analyze the reported efficacy of hyperbaric oxygen therapy versus microvascular free flap in ORN.MethodsThis review was conducted using the Preferred Reporting Items for Systematic Review & Meta-Analysis (PRISMA) guidelines. A systematic review search strategy was developed by a librarian (JED). The search was performed in the following databases on March 8, 2023: PubMed, EMBASE, andClinicalTrials.gov. Two reviewers independently assessed the titles, abstracts, and full-text manuscripts based on predetermined inclusion and exclusion criteria. The risk of bias of the final included studies was assessed using the Newcastle-Ottawa Scale. final included studies were assessed using the Newcastle-Ottawa risk of bias assessment, and analyses were performed using risk ratios.ResultsThe initial search yielded 1,614 articles with 407 undergoing full-text review. Ultimately, nine studies met the eligibility criteria and were included in the review. In total, 339 patients were included across the nine studies. Each of the nine studies reported on resolution of ORN with HBOT versus surgical free flap, with six studies showing significant differences in outcomes, with surgical free flap yielding significantly higher complete resolution of ORN compared to HBOT (RR 0.42, 95% CI 0.2-0.85; RR 0.07, 95% CI 0-0.99; RR 0.04, 95% CI 0-0.57; RR 0.12, 95% CI 0.04-0.34; RR 0.21, 95% CI 0.08-0.54; RR 0.43, 95% CI 0.24-0.78). Three studies showed no significant differences in ORN resolution (RR 0.33, 95% CI 0.03-4.19; RR 0.33, 95% CI 0.03-4.19; RR 0.34, 95% CI 0.11-1.09). The summary outcome of ORN resolution found a significant difference between surgical free flap and HBOT (RR 0.28, 95% CI 0.17-0.45).ConclusionsDespite the traditional practice of recommending HBOT for ORN treatment, our meta-analysis suggests that HBOT provides little benefit, especially for later stages of disease, and that surgical intervention via surgical free flap yields superior outcomes. However, there may be some benefit of HBOT in conservative management of early and intermediate cases of ORN. Surgical reconstruction with microvascular free flap may be a superior alternative to HBOT in the management of these patients.
Comparative performance of COVID-19 Test Methods in Healthcare Workers during the Omicron Wave
Authors: Tornberg Emma , Tomlinson Alexander , Oshiro Nicholas T.T. , Derfalie Esraa , Curlin Marcel E. 
Published: September 2023

AbstractIntroductionThe COVID-19 pandemic presents unique requirements for accessible, reliable testing, and many testing platforms and sampling techniques have been developed. However, not all test methods have been systematically compared to each other or a common gold standard, and the performance of tests developed in the early epidemic have not been consistently re-evaluated in the context of newly emerging SARS-CoV-2 variants.MethodsWe conducted a repeated measures study with adult healthcare workers presenting for SARS-CoV-2 testing. Participants were tested using seven test modalities: PCR with samples from the nasopharynx, oropharynx, and saliva; and BinaxNOW and iHealth antigen–based rapid detection tests (AgRDT) sampling the oropharynx and the nares. Test sensitivity was compared using any positive PCR test as the gold standard.Results325 individuals participated in the study. PCR tests were the most sensitive with saliva PCR at 0.957 ± 0.048, nasopharyngeal PCR at 0.877 ± 0.075, and oropharyngeal PCR at 0.849 ± 0.082. Standard nasal rapid antigen tests were less sensitive but roughly equivalent at 0.613 ± 0.110 for BinaxNOW brand and 0.627 ± 0.109 for iHealth. Oropharyngeal rapid antigen tests were the least sensitive with BinaxNOW and iHealth brands at 0.400 ± 0.111 and 0.311 ± 0.105 respectively.ConclusionPCR remains the most sensitive testing modality for COVID-19, with saliva PCR being significantly more sensitive than oropharyngeal PCR and equivalent to nasopharyngeal PCR. Saliva testing has patient comfort and financial benefits, making it a preferred testing modality. Nasal AgRDTs are less sensitive than PCR though more accessible and convenient.
Healthcare Costs and Healthcare Utilization Outcomes of Vitamin D3 Supplementation at 5000 IU Daily During a 10.9 month Observation Period within a Pragmatic Randomized Clinical Trial
Authors: LaRiccia Patrick J. , Cafaro Teresa , John Dibato , van Helmond Noud , Mitrev Ludmil V. , Bandomer Brigid , Brobyn Tracy L. , Hunter Krystal , Roy Satyajeet , Ng Kevin Q. , Goldstein Helen , Tsai Alan , Thwing Denise , Maag Mary Ann , Chung Myung K. 
Published: September 2023

AbstractVitamin D insufficiency has been linked to multiple conditions including bone disease, respiratory disease, cardiovascular disease, diabetes, and cancer. Observational studies indicate lower healthcare costs and healthcare utilization with sufficient vitamin D levels. The secondary aims of our previously published pragmatic clinical trial of vitamin D3 supplementation were comparisons of healthcare costs and healthcare utilization. Comparisons were made between the vitamin D3 at 5000 IU supplementation group and a non-supplemented control group. Costs of care between the groups were not statistically different. Vitamin D3 supplementation reduced healthcare utilization in four major categories: hospitalizations for any reason (rate difference: -0.19 per 1000 person-days, 95%-CI: -0.21 to -0.17 per 1000 person-days,p< 0.0001); ICU admissions for any reason (rate difference: -0.06 per 1000 person-days, 95%-CI: -0.08 to -0.04 per 1000 person-days,p< 0.0001); emergency room visits for any reason (rate difference: -0.26 per 1000 person-days, 95%-CI: -0.46 to -0.05 per 1000 person-days,p= 0.0131; and hospitalizations due to Covid-19 (rate difference: -8.47X10−3per 1000 person-days, 95%-CI: -0.02 to -1.05X10−3per 1000 person-days,p= 0.0253). Appropriately powered studies of longer duration are recommended for replication of these utilization findings and analysis of cost differences.
MODELING CYSTIC FIBROSIS PATIENT PROGNOSIS: NOMOGRAMS TO PREDICT LUNG TRANSPLANTATION AND SURVIVAL PRIOR TO HIGHLY EFFECTIVE MODULATOR THERAPY
Authors: Piccorelli Annalisa V. , Nick Jerry A. 
Published: September 2023

ABSTRACTBackgroundThe duration of time a person with cystic fibrosis (pwCF) spends on the lung transplant waitlist is dependent on waitlist and post-transplant survival probabilities and can extend up to 2 years. Understanding the characteristics involved with lung transplant and survival prognoses may help guide decision making by the patient, the referring CF Center and the transplant team.MethodsThis study seeks to identify clinical predictors of lung transplant and survival of individuals with CF using 29,847 subjects from 2003-2014 entered in the Cystic Fibrosis Foundation Patient Registry (CFFPR).ResultsPredictors significant (p ≤ 0.05) in the final logistic regression model predicting probability of lung transplant/death were: FEV1(% predicted), BMI, age of diagnosis, age, number of pulmonary exacerbations, race, sex, CF-related diabetes (CFRD), corticosteroid use, infections withB. cepacia, P. aeruginosa, S. aureus, MRSA, pancreatic enzyme use, insurance status, and consecutive ibuprofen use for at least 4 years. The final Cox regression model predicting time to lung transplant identified these predictors as significant FEV1(% predicted), BMI, age of diagnosis, age, number of pulmonary exacerbations, race, sex, CF-related diabetes (CFRD), corticosteroid use, infections withB. cepacia, P. aeruginosa, S. aureus, MRSA, pancreatic enzyme use, and consecutive ibuprofen use for at least 4 years. The concordance indices were 0.89 and 0.92, respectively.ConclusionsThe models are translated into nomograms to simplify investigation of how various characteristics relate to lung transplant and survival prognosis individuals with CF not receiving highly effective CFTR modulator therapy.
Adverse childhood experiences across Multiracial and monoracial groups with and without Indigenous ancestry
Authors: Lam-Hine Tracy , Riddell Corinne A. , Bradshaw Patrick T. , Omi Michael , Allen Amani M. 
Published: September 2023

AbstractAdverse childhood experiences (ACEs) are linked to increased risk of a host of health outcomes in adulthood. Descriptive ACEs prevalence studies have previously identified that Multiracial people have the highest mean ACE score of any racial group, but do not offer explanations for these disparities. However, Multiracial people form one of the fastest-growing populations in the US, and the largest subgroup of Multiracial people is those that claim American Indian/Native American (AI/NA) ancestry. Mean ACE counts (scores) are also high among the AI/NA population, which may reflect impacts of land occupation and structural racism. This descriptive study uses data from the National Longitudinal Study of Adolescent to Adult Health (Add Health) to test the hypothesis that mean ACE scores and prevalence of ACE components are higher among Multiracial AI/NA participants than Multiracial non-AI/NA participants. Mean scores were highest among AI/NA (mean = 3.21, 95% CI: 2.54, 3.97), Multiracial AI/NA (2.95, 95% CI: 2.71, 3.18), Multiracial non-AI/NA (2.88, 95% CI: 2.57, 3.19), and Black (2.84, 95% CI: 2.65, 3.02) groups. Differences in mean ACE scores and prevalence of ACE components between the two Multiracial groups were all insignificant. Results from this study did not support our hypothesis, suggesting that the Multiracial population’s high ACE scores are not driven primarily by those with AI/NA ancestry. Future studies should repeat this analysis in larger datasets and explore other determinants of high mean ACE scores among the Multiracial population.
Near-term forecasting of Covid-19 cases and hospitalisations in Aotearoa New Zealand
Authors: Plank Michael J. , Watson Leighton , Maclaren Oliver J. 
Published: September 2023

AbstractNear-term forecasting of infectious disease incidence and consequent demand for acute healthcare services can support capacity planning and public health responses. Despite well-developed scenario modelling to support the Covid-19 response, Aotearoa New Zealand lacks advanced infectious disease forecasting capacity. We develop a model using Aotearoa New Zealand’s unique Covid-19 data streams to predict reported Covid-19 cases, hospital admissions and hospital occupancy. The method combines a semi-mechanistic model for disease transmission to predict cases with Gaussian process regression models to predict the fraction of reported cases that will require hospital treatment. We evaluate forecast performance against out-of-sample data over the period from 2 October 2022 to 23 July 2023. Our results show that forecast performance is reasonably good over a 1-3 week time horizon, although generally deteriorates as the time horizon is lengthened. The model has been operationalised to provide weekly national and regional forecasts in real-time. This study is an important step towards development of more sophisticated situational awareness and infectious disease forecasting tools in Aotearoa New Zealand.Author summaryThe emergency phase of the Covid-19 pandemic has ended, but Covid-19 continues to put significant additional load on stretched healthcare systems. Forecasting the number of hospital cases caused an infectious disease like Covid-19 over the next few weeks can help with effective planning and response. The ability to forecast reliably requires timely, high-quality data and accurate mathematical models. We have developed a model for forecasting the number of Covid-19 cases and hospitalisations in Aotearoa New Zealand. The model works in two stages: firstly predicting the number of new cases and secondly estimating the proportion of those cases that will need hospital treatment. The model produces a range of likely values, which is important because is impossible to predict with 100% accuracy. We show that the model does a reasonably good job of predicting hospitalisations up to 3 weeks ahead. The model has been used by public health agencies in Aotearoa New Zealand to help with healthcare capacity planning.